We are committed to developing best-in-class therapeutics for patients with high unmet need across a wide range of diseases.

We aim to discover and develop innovative therapeutics across a broad range of diseases in order to realize the transformative potential of previously undruggable targets, including SLCs. We are advancing an internal pipeline of programs in immune-mediated diseases, oncology and metabolite-dependent diseases. Collaborations with biopharma partners are a critical part of our strategy, giving us additional opportunities to leverage the RAPID platform and address patient needs, including in therapeutic areas outside of our current internal focus.



Back to Top

This links to an external website. Merus is not responsible for any third party content.